LigoCyte hires Don Beeman as CEO as company prepares for first phase 1 trial

By E. Janene Geiss

Philadelphia, May 18 - LigoCyte Pharmaceuticals said Thursday that Donald Beeman has joined the company as its new chief executive officer.

Most recently the president and co-founder of Topaz Pharmaceuticals LLC, Beeman has more than 25 years experience in top executive positions in the pharmaceutical industry, according to a company news release.

Before joining Topaz, Beeman was the vice president of U.S. commercial operations for Merck's vaccine division.

The company is preparing to take to the clinic its Norovirus vaccine, which is a mucosal vaccine for the prevention of Norovirus infection, a temporarily debilitating illness that afflicts nearly 23 million Americans annually, officials said.

Beeman will lead the company as it begins its first human clinical phase 1 trial, officials said.

LigoCyte is a Bozeman, Mont., pharmaceutical company with a focus on treating inflammatory and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.